Despite what the name suggests, Polyendocrine Metabolic Ovarian Syndrome isn’t just about ovaries—or cysts, for that matter. In fact, many people diagnosed with PMOS don’t have any ovarian cysts at all. Confusing? You’re not alone. The name dates back to how the condition was first described, but science has come a long way since then. Today, we understand that PCOS is really a complex hormonal and metabolic condition that affects far more than reproductive health.
At its core, PMOS is about hormonal imbalance. When key hormones like insulin, androgens (like testosterone), and others are out of sync, they can create a domino effect throughout the body. This hormonal miscommunication can lead to irregular periods, acne, weight changes, hair loss or excess hair growth, difficulty with ovulation or fertility—and that’s just the shortlist. But here’s the thing: PMOS doesn’t follow a single pattern. Some women experience textbook symptoms. Others don’t fit the mold at all. That’s part of what makes PMOS so challenging—and why understanding your unique experience matters.
So, how can the PMOS Association help?
We’re here to offer more than definitions. We’re here to offer direction. Whether you’re newly diagnosed, still searching for answers, or years into your journey and feeling stuck, we’re committed to helping you make sense of PMOS—and make progress.
Here’s what you’ll find at PMOSA:
✅ Reliable, science-backed information about what PMOS is (and isn’t)
💬 Supportive communities of people who understand exactly what you’re going through
🧬 Resources for navigating fertility, metabolic health, nutrition, and more
🧠 Education for providers who want to better support their PMOS patients
🙋♀️ Advocacy to make sure PMOS is recognized, researched, and respected
No fluff. No fad cures. Just real support, grounded in evidence and compassion.
At PMOSA, we believe every person with PCOS deserves to be informed, empowered, and heard. Wherever you are in your journey, we’re honored to walk with you.
pcos: Latest results from PubMed
CONCLUSION: EKWKM formed clinically meaningful and Rotterdam-based PCOS phenotype clusters. In contrast, the population survey clusters formed symptom-reporting patterns and are not meaningful PCOS phenotypes.
Published on: Thu, 15 Oct 2026 06:00:00 -0400
Authors: Priyanka D, Sumangali K,
Polycystic ovarian syndrome (PCOS) is a common endocrine disorder in women of reproductive age. Metal ions can disrupt antioxidant defenses, alter the endometrial environment, and contribute to its pathophysiology. To compare element levels in menstrual effluent (ME) between women with PCOS and healthy controls, and to assess their association with antioxidant defence mechanisms, a case-control study was conducted among women diagnosed with PCOS according to the Rotterdam criteria. ME was...
Published on: Wed, 14 Oct 2026 06:00:00 -0400
Authors: Aparna Eledath Kolasseri, Ramasamy Tamizhselvi, Sivaraman Jayanthi,
CONCLUSIONS: Women with PCOS achieved metabolic improvements equivalent to those without PMOS through a multidisciplinary telehealth model despite presenting with a more adverse metabolic profile at baseline.
Published on: Wed, 14 Oct 2026 06:00:00 -0400
Authors: Heather G Huddleston, Rachel Blank, Nandita Sommers, Nicole Hellman, Felice Ramallo, Tiffany Pham, Karla Lindquist,
CONCLUSION: Women with PMOS characterized by lower vitamin D concentrations alongside higher AMH, IL-6, IL-8, and BMI compared to healthy controls. Larger longitudinal and prospective interventional studies are required to clarify causality and determine if vitamin D supplementation improves clinical outcomes.
Published on: Wed, 14 Oct 2026 06:00:00 -0400
Authors: Roba Bdeir, Nour Al-Sawalha, Hasan Rawashdeh, Ruba Malkawi, Ola Alrousan,
Polycystic ovary syndrome (PCOS) is a common endocrine disorder characterised by hormonal and metabolic disturbances that are often present before pregnancy. Emerging evidence suggests that women with PCOS may be more susceptible to nausea and vomiting of pregnancy (NVP), particularly moderate-to-severe symptoms, raising interest in the potential biological links between these conditions. This narrative review examines the endocrine and metabolic characteristics of PCOS during early pregnancy...
Published on: Wed, 14 Oct 2026 06:00:00 -0400
Authors: Zhuwei Gao, Jiaxing Feng, Hongli Ma, Hui Chang, Yu Wang, Baichao Shi, Yabing Li, Yue Zhang, Xiaoke Wu,
CONCLUSION: Current evidence indicates that any association between PCOS/PMOS and AD risk is likely mediated by metabolic comorbidities, particularly IR and obesity, rather than an independent effect of PCOS/PMOS itself. However, clinical evidence for increased PCOS/PMOS risk for cognitive vulnerability and dementia remain inconsistent and cognitive benefits from PCOS/PMOS-specific interventions are lacking. Clinical focus should therefore remain on optimizing metabolic health, while...
Published on: Wed, 14 Oct 2026 06:00:00 -0400
Authors: Mina Amiri, Armita Kakavand Hamidi, Daniel L Farkas, Richard P Buyalos, Ricardo Azziz,
CONCLUSION: PCOS is an emerging, increasingly shared public health problem across the GCC, with a burden exceeding international benchmarks, driven predominantly by population growth and associated with rising obesity; forecasting models suggest continued increases in the coming decades. Increased surveillance, standardized early diagnosis, and integrated reproductive-metabolic health strategies are needed across the region.
Published on: Wed, 14 Oct 2026 06:00:00 -0400
Authors: Raseel B Almutairi, Renad S Alrebh, Raghad M Alotaibi, Somayah H Almaimouni, Batol H Boheliga, Danah M Al-Awad, Batool H Alsadig, Salma M Alawadhi, Lamar A Alghanmi, Anwar N Alsadah, Fatimah M Alsayegh, Adel S Almutairi, Layan S Alwadei, Nourah H Al Qahtani,
CONCLUSION: Sitagliptin has potential impact on the hormonal, metabolic and clinical aspects of PCOS, and an exploratory effect on reproductive function. This makes it a potentially promising option for managing this complex condition.
Published on: Wed, 14 Oct 2026 06:00:00 -0400
Authors: Ahmed E Altyar, Dina Y Dessouky, Sara Abdallah Mohamed Salem, Heba F Salem, Marian S Boshra,
CONCLUSIONS: In this exploratory six-month longitudinal observational study, early-stage female BD patients with relatively mild symptoms did not show a statistically significant increase in PCOS incidence when untreated. VPA treatment was associated with significant increases in oligomenorrhea/amenorrhea, AMH, and FAI, suggesting changes in PCOS-related reproductive markers. These findings support careful reproductive and metabolic monitoring when VPA is prescribed to women with BD, while...
Published on: Wed, 14 Oct 2026 06:00:00 -0400
Authors: Jieyu Liu, Jing Huang, Ziwei Teng, Yusi Fu, Yan Tan, Yue Qin, Haiyu Chen, Minghui Liu, Jindong Chen, Haishan Wu, Ying Wu, Guotao Wang,
CONCLUSION: Yoga offers a holistic, integrated mind-body approach to managing the endocrine, metabolic, and reproductive dysfunction in PMOS and lowers the risk of developing long-term comorbidities.
Published on: Tue, 13 Oct 2026 06:00:00 -0400
Authors: Deepika Kumari, Hanuman Prasad Sharma, Yashwant Kumar, Neena Malhotra, Reeta Mahey, Rima Dada,
Polycystic ovary syndrome (PCOS) is a complex endocrine disorder frequently associated with granulosa cell dysfunction. However, its underlying molecular mechanisms remain unclear. Therefore, we aimed to examine the role of APPL1 in PCOS and determine whether it attenuates oxidative stress and ferroptosis by modulating mitophagy in granulosa cells. An in vitro PCOS model was established by treating KGN cells with dehydroepiandrosterone (DHEA), with or without concurrent APPL1 overexpression. An...
Published on: Tue, 13 Oct 2026 06:00:00 -0400
Authors: Shentao Lu, Xueru Yang, Yingxia He, Hua Linghu, Xuemei Fu,
CONCLUSION: EM and PCOS exhibit geographically divergent burden patterns with differing socioeconomic gradients across Europe, underscoring the need for regionally differentiated reproductive health strategies.
Published on: Tue, 13 Oct 2026 06:00:00 -0400
Authors: Chanchan Ma, Shibo Huang, Lihuan Song, Ying Luo, Honglan Zhu,
In women aged 35 years or younger with diminished ovarian reserve (DOR), we evaluated whether two pretreatment markers, anti-Müllerian hormone (AMH) and antral follicle count (AFC), can stratify the risk of poor ovarian response (POR) before stimulation. This retrospective cohort included IVF/ICSI cycles from four centres in Zhejiang, China (2022-2025). Of 1,754 DOR-eligible cycles, 157 were removed in two post-hoc phenotype-cleaning exclusions (PCOS, n = 139; AMH ≥5 ng/mL without PCOS, n = 18),...
Published on: Tue, 13 Oct 2026 06:00:00 -0400
Authors: Yanning Lv, Jiahao Fang, Haiyan Yang, Jianying He, Lihua Xia, Honglian Wu,
CONCLUSION: Longitudinal evidence supports a chain mediating pathway wherein elevated fear of negative evaluation at baseline is prospectively associated with subsequent increases in appearance social pressure and declines in body image, which in turn correspond to higher levels of social anxiety in women with PCOS. Findings support the potential utility of early psychological screening and targeted interventions addressing maladaptive cognitions and body image disturbances, although causal...
Published on: Tue, 13 Oct 2026 06:00:00 -0400
Authors: Li Chen, Qiuyan Liang, Dexin Lv, Lejuan Zeng, Xiangfen Zeng, Huiying Cai, Saiqiong Chen,
CONCLUSION: A 12-week EHDP-modified ketogenic diet was associated with improvements in body composition, metabolic indices, reproductive hormones, and clinical symptoms in Chinese patients with PMOS and obesity, without clinically significant safety concerns. This culturally adapted approach may offer a practical nutritional strategy for this population; controlled trials are warranted to confirm these findings.
Published on: Tue, 13 Oct 2026 06:00:00 -0400
Authors: Qiuxia Chen, Pianhong Zhang, Minhui Dai, Yuting Feng, Xiao Yu, Pingping Zhao, Xiaoming He,